$PACB earnings report

PacBio Announces Third Quarter 2026 Financial Results. AlphAI read Pacific Biosciences of California's Q3 FY2026 filing as mixed. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readPACB · Q3 2026 · ended September 30, 2026

PacBio Announces Third Quarter 2026 Financial Results

→Mixed quarter

Revenue increased to $40.6 million, supported by instrument and service revenue and higher Vega placements, but consumable revenue declined, gross margins contracted, and the company remained loss-making.

Revenue
$40.6M
Consumable revenue
$20.8M
Gross margin · GAAP
33%
EPS · GAAP
$ (0.12)
Full year 2026 outlook
$155 million to $160 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, Q3 2026GAAP$40.6M––
Product revenue, Q3 2026GAAP$34.00M––
Service and other revenue, Q3 2026GAAP$6.56M––
Consumable revenue, Q3 2026other$20.8M––
Instrument revenue, Q3 2026other$13.2M––
GAAP gross profit, Q3 2026GAAP$13.5M––
Non-GAAP gross profit, Q3 2026non-GAAP$14.6M––
GAAP gross margin, Q3 2026GAAP33%––
Non-GAAP gross margin, Q3 2026non-GAAP36%––
Research and development expense, Q3 2026GAAP20.22M––
Sales, general and administrative expense, Q3 2026GAAP29.42M––
GAAP total operating expense, Q3 2026GAAP$50.5M––
Non-GAAP total operating expense, Q3 2026non-GAAP$47M––
Operating loss, Q3 2026GAAP−37.00M––
Interest expense, Q3 2026GAAP−2.06M––
Other income, net, Q3 2026GAAP1.48M––
Loss before income taxes, Q3 2026GAAP−37.58M––
Income tax provision, Q3 2026GAAP269K––
GAAP net loss, Q3 2026GAAP$37.8M––
Non-GAAP net loss, Q3 2026non-GAAP$32.8M––
GAAP basic net loss per share, Q3 2026GAAP$ (0.12)––
GAAP diluted net loss per share, Q3 2026GAAP$ (0.12)––
Non-GAAP basic net loss per share, Q3 2026non-GAAP$ (0.11)––
Weighted average basic shares outstanding, Q3 2026GAAP311.2M––
Weighted average diluted shares outstanding, Q3 2026GAAP311.2M––
Total revenue, nine months ended September 30, 2026GAAP116.7M––
Product revenue, nine months ended September 30, 2026GAAP98.49M––
Service and other revenue, nine months ended September 30, 2026GAAP18.26M––
GAAP gross profit, nine months ended September 30, 2026GAAP38.95M––
Non-GAAP gross profit, nine months ended September 30, 2026non-GAAP42.43M––
GAAP gross margin, nine months ended September 30, 2026GAAP33 %––
Non-GAAP gross margin, nine months ended September 30, 2026non-GAAP36 %––
GAAP total operating expense, nine months ended September 30, 2026GAAP128.9M––
Non-GAAP total operating expense, nine months ended September 30, 2026non-GAAP152.9M––
GAAP net loss, nine months ended September 30, 2026GAAP−$90.86M––
Non-GAAP net loss, nine months ended September 30, 2026non-GAAP−$110.7M––
GAAP basic net loss per share, nine months ended September 30, 2026GAAP$ (0.29)––
Non-GAAP basic net loss per share, nine months ended September 30, 2026non-GAAP$ (0.36)––
Cash and investments, September 30, 2026GAAP$199.4M––
Convertible senior notes, net, September 30, 2026GAAP643.1M––
Stockholders' equity (deficit), September 30, 2026GAAP−61.38M––

Segments

SegmentRevenueq/qy/y
Consumable revenueContinued instrument and consumables demand; over half of Revio consumables revenue was tied to SPRQ-Nx.$20.8M––
Instrument revenueThe company delivered 35 new Vega systems in the quarter and launched SPRQ-Nx for Vega in late August.$13.2M––
Service and other revenueNo specific revenue driver was reported.$6.6M––

Full year 2026 outlook

  • Revenue$155 million to $160 million

What drove it

  • Vega system placements were 35, up 9% year-over-year, and more than 90% were sold to new customers.
  • Revio system placements were 15, compared to 13 in Q3 2025.
  • Over half of Revio consumables revenue was tied to SPRQ-Nx, and two-thirds of the Revio installed base opted to upgrade software for use of SPRQ-Nx by the end of the quarter.
  • Non-GAAP operating expenses declined primarily because of lower personnel and related expenses resulting from restructuring initiatives.
  • PacBio cited higher memory costs and Vega manufacturing transition costs as the primary causes of the non-GAAP gross-margin decline.

Concerns

  • Consumable revenue was $20.8 million, compared to $21.3 million in Q3 2025.
  • Annualized Revio pull-through per system was ~$204,000, compared to ~$236,000 in Q3 2025.
  • GAAP gross margin was 33%, compared to 41%, and non-GAAP gross margin was 36%, compared to 42%.
  • PacBio reported a GAAP net loss of $37.8 million and a non-GAAP net loss of $32.8 million.
  • Jim Gibson stepped down as CFO; Mark Van Oene was appointed interim CFO while PacBio searches for a new CFO.
  • Cash and investments were $ 199,418 (in thousands), while convertible senior notes, net were 643,058 (in thousands).

What to watch

  • Execution of SPRQ-Nx adoption across the Revio installed base and the late-August launch of SPRQ-Nx for Vega.
  • Whether higher Vega placements and new-customer sales translate into consumable revenue growth and improved annualized Revio pull-through.
  • The effect of memory costs and Vega manufacturing transition costs on gross margin.
  • Progress on the full-year 2026 revenue outlook of $155 million to $160 million.
  • The CFO search following the appointment of an interim CFO.

Balance sheet and cash flow

  • Cash and investments were $ 199,418 (in thousands) as of September 30, 2026, compared to $ 279,506 (in thousands) as of December 31, 2025.
  • Convertible senior notes, net were 643,058 (in thousands) as of September 30, 2026, compared to 645,382 (in thousands) as of December 31, 2025.
  • Inventory, net was 60,278 (in thousands) as of September 30, 2026, compared to 49,285 (in thousands) as of December 31, 2025.
  • Stockholders' equity (deficit) was (61,380) (in thousands) as of September 30, 2026, compared to 5,349 (in thousands) as of December 31, 2025.

Analysis

PacBio reported Q3 2026 revenue of $40.6 million, compared with $38.4 million in Q3 2025. The quarter's revenue mix showed instrument revenue of $13.2 million and service and other revenue of $6.6 million, versus $11.3 million and $5.8 million, respectively, in the prior-year quarter. Consumable revenue was $20.8 million, compared with $21.3 million. Product revenue in the condensed consolidated statements was $ 34,002 (in thousands), compared with $ 32,597 (in thousands), while service and other revenue was $ 6,562 (in thousands), compared with $ 5,844 (in thousands).

Instrument activity improved, with 35 Vega system placements compared with 32, a reported increase of 9% year-over-year. More than 90% of Vega systems were sold to new customers. Revio placements were 15 compared with 13, while annualized Revio pull-through per system declined to ~$204,000 from ~$236,000. PacBio said over half of Revio consumables revenue was tied to SPRQ-Nx and two-thirds of the Revio installed base opted to upgrade software for SPRQ-Nx by quarter-end.

Margins contracted despite the revenue increase. GAAP gross profit was $13.5 million compared with $15.9 million, and GAAP gross margin was 33% compared with 41%. Non-GAAP gross profit was $14.6 million compared with $16.2 million, while non-GAAP gross margin was 36% compared with 42%. The company attributed the non-GAAP margin decline primarily to higher memory costs and Vega manufacturing transition costs.

Cost actions reduced operating expense. GAAP operating expenses totaled $50.5 million versus $54.8 million, and non-GAAP operating expenses were $47.0 million versus $53.9 million, primarily reflecting lower personnel and related expenses from restructuring initiatives. GAAP net loss was $37.8 million compared with $38.0 million, and non-GAAP net loss was $32.8 million compared with $36.8 million. Cash and investments stood at $ 199,418 (in thousands) at September 30, 2026, compared with $ 279,506 (in thousands) at December 31, 2025, and convertible senior notes, net were 643,058 (in thousands).

PacBio now expects full-year 2026 revenue of $155 million to $160 million. The filing did not provide gross-margin, operating-expense, tax-rate, earnings, cash-flow, or capital-allocation guidance. Management also disclosed a CFO transition, with Jim Gibson stepping down, Mark Van Oene appointed interim CFO, and Bill Meyer appointed Chief Accounting Officer.

Management, verbatim

PacBio is entering an exciting phase as the investments we’ve made in our technology begin to unlock new opportunities. SPRQ-Nx is changing the economics of HiFi sequencing, while growing clinical adoption and strategic collaborations in population genomics and AI are expanding the markets we can serve. We have a tremendous opportunity ahead of us, and my focus is clear: sharpen our execution, prioritize what matters most, and translate the strength of our technology into sustainable growth .

Mark Van Oene, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-quarter financial results for Q3 2026 metrics were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Capital returns, including share repurchases and dividends, were not reported.
  • Full-year 2026 guidance for gross margin, operating expenses, tax rate, net income or loss, EPS, operating cash flow, and free cash flow was not reported.
  • Prior outlook was not provided, so comparison with prior guidance is unavailable.
  • GAAP and non-GAAP diluted EPS beyond the GAAP diluted net loss per share line were not separately reported.
  • A tax rate was not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2 FY2026

AlphAI · Earnings readPACB · Q2 2026 · ended June 30, 2026

PacBio reported Q2 2026 revenue of $39.0 million, with higher consumable revenue but lower instrument and service and other revenue, while GAAP and non-GAAP gross margins and net results were below the prior-year quarter.

→Mixed quarter

Consumable revenue and Revio system placements increased versus Q2 2025, but total revenue, instrument revenue, service and other revenue, gross margins, and GAAP and non-GAAP net loss results were unfavorable versus the prior-year quarter.

Revenue
$39M
Consumable revenue
$20.1M
Gross margin · GAAP
32%
EPS · non-GAAP
$0.14
full year 2026 outlook
$155 million to $165 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Revenueother$39M––
Consumable revenueother$20.1M––
Instrument revenueother$12.8M––
Service and other revenueother$6.1M––
Revio system placementsother20––
Vega system placementsother26––
Annualized Revio pull-through per systemother~$202,000––
Gross profitGAAP$12.6M––
Gross profitnon-GAAP$13.9M––
Gross marginGAAP32%––
Gross marginnon-GAAP36%––
Operating expensesGAAP$57.2M––
Operating expensesnon-GAAP$56.1M––
Share-based compensationGAAP$8.6M––
Net lossGAAP$44.7M––
Net lossnon-GAAP$41.9M––
Net loss per shareGAAP$0.14––
Net loss per sharenon-GAAP$0.14––

Segments

SegmentRevenueq/qy/y
Consumable revenueThe release cited growing consumables.$20.1M––
Instrument revenueInstrument revenue included both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer.$12.8M––
Service and other revenueNot specified in the release.$6.1M––

full year 2026 outlook

  • Revenue$155 million to $165 million

What drove it

  • The Company commenced its full rollout of SPRQ-Nx chemistry.
  • PacBio commenced global commercial rollout of SPRQ-Nx, with whole genome sequencing at $345 USD list price per genome.
  • PacBio commenced sequencing and sample delivery for Basecamp Research, described as its largest population-scale program to date.
  • The Company implemented restructuring actions primarily to streamline marketing and R&D organizations, strengthen the go-to-market commercial organization, and drive greater cost discipline going forward.

Concerns

  • GAAP gross margin was 32% compared to 37% for the second quarter of 2025, while non-GAAP gross margin was 36% compared to 38%.
  • The decline in non-GAAP gross margin was primarily driven by higher compute and memory costs, Vega manufacturing transition costs, and lower Revio average selling prices associated with strategic multi-system customer placements.
  • GAAP net loss was $44.7 million compared to $41.9 million for the second quarter of 2025, and non-GAAP net loss was $41.9 million compared to $40.0 million.
  • Vega system placements were 26 compared to 38, and annualized Revio pull-through per system was ~$202,000 compared to ~$219,000.

What to watch

  • Execution of the full rollout of SPRQ-Nx chemistry.
  • Revenue performance against full-year 2026 guidance of $155 million to $165 million.
  • The effects of restructuring actions on cost discipline and the go-to-market commercial organization.
  • Revio and Vega system placements, consumable revenue, and annualized Revio pull-through per system.
  • The effect of compute and memory costs, Vega manufacturing transition costs, and Revio average selling prices on gross margin.

Balance sheet and cash flow

  • Ending cash, cash equivalents, and investments: $236.9 million, compared to $314.7 million in Q2 2025.

Analysis

PacBio reported revenue of $39.0 million for Q2 2026, compared to $39.8 million in Q2 2025. Consumable revenue was $20.1 million compared to $18.9 million, while instrument revenue was $12.8 million compared to $14.2 million and service and other revenue was $6.1 million compared to $6.7 million. The release attributed total revenue to growing consumables and new Revio and Vega placements as the Company commenced its full rollout of SPRQ-Nx chemistry.

System activity was mixed. Revio system placements were 20 compared to 15, whereas Vega system placements were 26 compared to 38. Annualized Revio pull-through per system was ~$202,000 compared to ~$219,000. Instrument revenue included both single-system and multi-system orders, including an order for several Revio systems from a new population-scale customer.

Gross profitability weakened versus Q2 2025. GAAP gross profit was $12.6 million compared to $14.7 million and GAAP gross margin was 32% compared to 37%. Non-GAAP gross profit was $13.9 million compared to $15.2 million and non-GAAP gross margin was 36% compared to 38%. PacBio identified higher compute and memory costs, Vega manufacturing transition costs, and lower Revio average selling prices associated with strategic multi-system customer placements as the primary drivers of the non-GAAP gross-margin decline.

Operating expenses were lower year over year, with GAAP operating expenses of $57.2 million compared to $59.5 million and non-GAAP operating expenses of $56.1 million compared to $58.1 million. However, GAAP net loss was $44.7 million compared to $41.9 million, and non-GAAP net loss was $41.9 million compared to $40.0 million. The Company implemented restructuring actions focused on marketing and R&D streamlining, commercial go-to-market strengthening, and future cost discipline.

PacBio expects full-year 2026 revenue of $155 million to $165 million. The balance-sheet figure reported was ending cash, cash equivalents, and investments of $236.9 million, compared to $314.7 million in Q2 2025. Key reported execution items are the global commercial rollout of SPRQ-Nx, sequencing and sample delivery for Basecamp Research, and the Company’s ability to manage the cost and pricing factors identified in its gross-margin commentary.

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for revenue, revenue categories, system placements, annualized Revio pull-through per system, gross profit, gross margin, operating expenses, net loss, and net loss per share.
  • Year-over-year percentage changes for revenue, revenue categories, system placements, annualized Revio pull-through per system, gross profit, gross margin, operating expenses, net loss, and net loss per share.
  • GAAP and non-GAAP operating income or loss.
  • Operating cash flow.
  • Free cash flow.
  • Debt.
  • Share repurchases.
  • Dividends.
  • Guidance for gross margin, operating expenses, tax rate, EPS, net income or loss, operating cash flow, or free cash flow.
  • Prior-period financial outlook for comparison with reported results.
  • Named executive quotes.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about PACB earnings dates

When is Pacific Biosciences of California's next earnings date?
AlphAI has no date for PACB yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.